SAN DIEGO--(BUSINESS WIRE)--June 8, 2006--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH - News) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase I/II dose ranging human clinical trial with its investigational compound NEUMUNE(TM) (HE2100) in patients at high risk of developing healthcare-associated (nosocomial) infections. Hollis-Eden’s goal in this trial will be to establish the safety of NEUMUNE in this population, and to help identify the optimal patient subsets for further study in Phase II efficacy trials.
